Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical...

Area of Science:

• Pharmacology
• Toxicology
• Clinical Chemistry

Background:

• Opioid use disorder (OUD) presents a global health challenge.
• Current urine drug screening for OUD treatment relies on immunoassays with binary (yes/no) results.
• Variability in analytical cutoffs complicates comparisons between clinical studies.

Purpose of the Study:

• To determine if quantitative urinalysis provides clinically meaningful data on OUD treatment efficacy.
• To assess how different analytical cutoffs influence the observed differences between OUD treatments.

Main Methods:

• Analysis of quantitative urine drug test data from a 31-week phase 3 trial comparing CAM2038 (buprenorphine extended-release SC injections) with sublingual buprenorphine/naloxone tablets.
• Urine samples analyzed using gas or liquid chromatography with mass spectrometry.
• Exploration of the European Medicines Agency (EMA)-directed primary endpoint using various cutoffs, including the lower limit of quantification (LLOQ).

Main Results:

• Quantitative analysis revealed higher percentages of opioid-negative samples with CAM2038 compared to sublingual buprenorphine/naloxone, particularly at higher cutoffs.
• Mean concentrations and cumulative opioid exposure over time favored CAM2038.
• The choice of analytical cutoff significantly influenced the magnitude of treatment differences observed.

Conclusions:

• Quantitative urinalysis provides more detailed information on opioid use during treatment than qualitative methods.
• Analytical thresholds are critical factors influencing the interpretation and comparison of clinical trial outcomes in OUD treatment.